Related Experiment Video
Updated: Jun 5, 2026
Fu's Subcutaneous Needling for Knee Osteoarthritis Pain
Published on: March 24, 2023
Transcriptome profiling and experimental validation identify FOS, RAC2, and TYROBP as potential biomarkers for Fu's
Huiqin Fang1, Yaping Li2, Jiaqin Li3
1Neurology Department, Qingdao Hiser Hospital Affiliated of Qingdao University (Qingdao Traditional Chinese Medicine Hospital), Qingdao, Shandong, China.
Background:
This study aimed to explore potential biomarkers and mechanisms underlying in the treatment of neuropathic pain (NP) with Fu's subcutaneous needling (FSN), employing a transcriptomics approach.
Methods:
In this study, RNA sequencing was performed in a rat model of chronic constriction injury treated with FSN and acupuncture methods. The FSN-related genes in the treatment of NP with FSN were obtained by overlapping the results of differential expression analysis. Potential biomarkers were identified by protein-protein interaction (PPI) analysis and machine learning. In addition, potential biomarkers were analyzed for functional enrichment, molecular regulatory networks, and drug prediction. Reverse transcription quantitative PCR (RT-qPCR) was employed to validate the expression levels of the biomarkers.
Results:
FOS, RAC2, and TYROBP were identified as potential biomarkers. Furthermore, mo-miR-92a-2-5p was predicted to co-target RAC2 and TYROBP. Twenty-five drugs were predicted to target FOS and four drugs were predicted to target RAC2 were also identified. FSN treatment enhanced and attenuated the expression of RAC2, TYROBP, and FOS, respectively.
Conclusion:
In this study, FOS, RAC2, and TYROBP were identified as potential biomarkers in the treatment of NP with FSN, providing a potential theoretical basis for NP treatment.
More Related Videos
08:20Efficacy of Fu's Subcutaneous Needling on Sciatic Nerve Pain: Behavioral and Electrophysiological Changes in a Chronic Constriction Injury Rat Model
Published on: June 30, 2023
09:39Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1
Published on: February 13, 2018